| Not Yet Recruiting | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy NCT07218692 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcino NCT07500831 | Qilu Hospital of Shandong University | N/A |
| Recruiting | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy NCT06863311 | Karie Runcie | Phase 2 |
| Recruiting | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot NCT07227415 | Pfizer | Phase 1 / Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma NCT07123090 | Stephanie Berg | Phase 2 |
| Recruiting | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and M NCT06391099 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Meta NCT06603155 | Duke University | N/A |
| Withdrawn | PSMA Therapy and Immunotherapy in Kidney Cancer NCT06361810 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Recruiting | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced NCT07028125 | Centre Francois Baclesse | Phase 4 |
| Not Yet Recruiting | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases NCT07043608 | Kelly Fitzgerald, MD | Phase 2 |
| Recruiting | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) NCT06835972 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Enrolling By Invitation | Drug Screening Using Novel IMD in Renal Cell Carcinoma NCT05700461 | Oliver Jonas | Phase 1 |
| Active Not Recruiting | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in P NCT06284564 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer NCT06399419 | Osel, Inc. | Phase 1 |
| Recruiting | Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib NCT06548867 | Gruppo Oncologico Italiano di Ricerca Clinica | — |
| Recruiting | Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) NCT04974671 | Yale University | Phase 2 |
| Active Not Recruiting | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spr NCT06132945 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study NCT05863351 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Recruiting | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients NCT05817903 | Consorzio Oncotech | Phase 2 |
| Recruiting | Measuring Oncological Value of Exercise and Statin NCT05796973 | Tampere University Hospital | Phase 3 |
| Terminated | A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic NCT05119010 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Recruiting | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With NCT05327686 | NRG Oncology | Phase 2 |
| Recruiting | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patien NCT05759923 | Molecure S.A. | Phase 1 |
| Active Not Recruiting | Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognost NCT05219318 | University Hospital, Bordeaux | Phase 3 |
| Unknown | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic NCT05259319 | Centre Georges Francois Leclerc | Phase 1 |
| Recruiting | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma NCT05155033 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma NCT05816642 | RenJi Hospital | N/A |
| Withdrawn | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma NCT04961320 | City of Hope Medical Center | N/A |
| Completed | A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Ca NCT05858749 | Pfizer | — |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma NCT04919122 | Duke University | — |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC NCT06607809 | Dr. Lutfi Kirdar Kartal Training and Research Hospital | — |
| Completed | Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy NCT05112627 | Mayo Clinic | — |
| Recruiting | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tum NCT05263050 | Fox Chase Cancer Center | Phase 2 |
| Unknown | Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma NCT05135832 | Herlev and Gentofte Hospital | N/A |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cance NCT05122546 | City of Hope Medical Center | Phase 1 |
| Terminated | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT05119335 | NiKang Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer NCT04603365 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Ce NCT04788095 | City of Hope Medical Center | N/A |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Completed | Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CT NCT04802824 | Imperial College London | — |
| Unknown | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carc NCT04262427 | The Christie NHS Foundation Trust | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Ki NCT04510597 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Urine Omics Predicting IO Therapy Responses in mRCC Patients NCT04712305 | National Taiwan University Hospital | — |
| Completed | Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) NCT04508725 | Stanford University | N/A |
| Active Not Recruiting | Cancer and Blood Pressure Management, CARISMA Study NCT04467021 | ECOG-ACRIN Cancer Research Group | N/A |
| Terminated | Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma NCT06884683 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Withdrawn | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer NCT03927248 | HealthPartners Institute | Phase 1 / Phase 2 |
| Recruiting | A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Ca NCT04299646 | Centre Francois Baclesse | Phase 2 |
| Terminated | Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure NCT07117409 | Azienda USL Reggio Emilia - IRCCS | — |
| Completed | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer NCT04337970 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma NCT04644432 | Herlev and Gentofte Hospital | Phase 2 |
| Active Not Recruiting | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer NCT04090710 | Ontario Clinical Oncology Group (OCOG) | Phase 2 |
| Completed | Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases NCT03967522 | Centre Leon Berard | Phase 2 |
| Completed | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma NCT04068831 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma NCT04049344 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations NCT03786796 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade NCT03474497 | Megan Daly, MD | Phase 1 / Phase 2 |
| Completed | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer NCT03829111 | City of Hope Medical Center | Phase 1 |
| Terminated | Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targ NCT03408652 | Centre Leon Berard | Phase 3 |
| Active Not Recruiting | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 NCT03284385 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Active Not Recruiting | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 | Nanobiotix | Phase 1 |
| Active Not Recruiting | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's NCT03729245 | Nektar Therapeutics | Phase 3 |
| Unknown | Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patient NCT04891055 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Terminated | INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise In NCT03692338 | Duke University | N/A |
| Active Not Recruiting | Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic NCT03647878 | Ipsen | — |
| Completed | Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib NCT04076787 | Pfizer | — |
| Active Not Recruiting | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT03587662 | M.D. Anderson Cancer Center | Phase 2 |
| Suspended | Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma NCT03575611 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma NCT03463681 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Active Not Recruiting | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcino NCT03541902 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcino NCT03428217 | Calithera Biosciences, Inc | Phase 2 |
| Withdrawn | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Met NCT03149159 | Medical University of South Carolina | Phase 2 |
| Completed | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers NCT03071328 | Duke University | EARLY_Phase 1 |
| Completed | Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion NCT03494816 | Scottish Clinical Trials Research Unit | Phase 2 |
| Completed | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal NCT03200717 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clea NCT03075423 | Goethe University | Phase 2 |
| Unknown | Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Can NCT02849535 | Hospices Civils de Lyon | N/A |
| Completed | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma NCT03149822 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Terminated | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line T NCT03140176 | Pfizer | — |
| Terminated | M8891 First in Human in Solid Tumors NCT03138538 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Completed | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab NCT03126331 | Case Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy NCT03055013 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcin NCT02789137 | Pfizer | — |
| Completed | Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classifi NCT03091465 | Spanish Oncology Genito-Urinary Group | — |
| Terminated | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued Wit NCT02959554 | AIO-Studien-gGmbH | Phase 2 |
| Completed | TIL Therapy for Metastatic Renal Cell Carcinoma NCT02926053 | Inge Marie Svane | Phase 1 |
| Completed | Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy NCT03891485 | National Cancer Institute, Naples | — |
| Completed | Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With NCT02944617 | City of Hope Medical Center | N/A |
| Withdrawn | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. NCT02867332 | Peking University | Phase 1 |
| Terminated | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers NCT03115801 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | Second Line Sorafenib After Pazopanib in Patients With RCC NCT02122003 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy NCT02864615 | Kidney Cancer Research Bureau | N/A |
| Terminated | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clea NCT02837991 | Celldex Therapeutics | Phase 1 |
| Terminated | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery NCT02595918 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma NCT02639182 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Unknown | A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma NCT02774200 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | Testosterone in Metastatic Renal Cell Carcinoma Patients NCT03379012 | Kidney Cancer Research Bureau | Phase 2 |
| Completed | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic NCT03013335 | UNICANCER | Phase 2 |
| Completed | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary T NCT02599324 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Terminated | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) NCT02447887 | Fox Chase Cancer Center | Phase 1 / Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopa NCT04462445 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Immunotherapy Study for Metastatic Renal Cell Cancer NCT02035358 | NewLink Genetics Corporation | Phase 1 |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and NCT02406521 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carc NCT02398552 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms NCT02150369 | Duke University | — |
| Unknown | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Pati NCT02330783 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Ca NCT03519542 | Spanish Oncology Genito-Urinary Group | — |
| Completed | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell NCT02231749 | Bristol-Myers Squibb | Phase 3 |
| Completed | Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First NCT02282579 | Spanish Oncology Genito-Urinary Group | — |
| Completed | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of NCT02187302 | NewLink Genetics Corporation | Phase 2 |
| Withdrawn | Functional Imaging in the Assessment of mRCC Response to Sunitinib NCT01977586 | Imperial College Healthcare NHS Trust | N/A |
| Terminated | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-N NCT02026960 | Duke University | N/A |
| Terminated | Optimizing Pazopanib Exposure in RCC Patients NCT02089802 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. | Phase 2 |
| Completed | A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community An NCT01917214 | Pfizer | — |
| Completed | Sutent Rechallenge In mRCC Patients NCT01827254 | Pfizer | — |
| Terminated | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Can NCT01784978 | Associació per a la Recerca Oncologica, Spain | Phase 2 |
| Terminated | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcin NCT01582672 | Argos Therapeutics | Phase 3 |
| Terminated | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma NCT02071641 | Amsterdam UMC, location VUmc | Phase 2 |
| Completed | Sequential Therapy in Metastatic Renal Cell Carinoma NCT01731158 | Central European Society for Anticancer Drug Research | Phase 2 |
| Terminated | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC NCT01673386 | AVEO Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Pazopanib in Second-line Therapy in Renal Cell Carcinoma NCT01577784 | Associació per a la Recerca Oncologica, Spain | Phase 2 |
| Completed | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) NCT01550367 | Leonard Appleman | Phase 1 / Phase 2 |
| Completed | A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney NCT01525017 | Mendus | Phase 1 |
| Completed | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Soli NCT01482156 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastase NCT01444807 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Terminated | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell C NCT01441414 | Pfizer | Phase 2 |
| Completed | Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma NCT01491672 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatme NCT02056587 | Kidney Cancer Research Bureau | Phase 4 |
| Completed | PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy NCT01415167 | Prometheus Laboratories | — |
| Completed | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failur NCT01266837 | iOMEDICO AG | Phase 4 |
| Completed | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma NCT01223027 | Novartis Pharmaceuticals | Phase 3 |
| Completed | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma NCT01265901 | Immatics Biotechnologies GmbH | Phase 3 |
| Terminated | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma NCT01342627 | Centro di Riferimento Oncologico - Aviano | Phase 2 |
| Completed | Phase II Study of Alternating Sunitinib and Temsirolimus NCT01517243 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastati NCT01136733 | Eisai Inc. | Phase 1 / Phase 2 |
| Completed | Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Re NCT01202032 | Centre Leon Berard | Phase 1 |
| Terminated | Cost Effectiveness Of Sunitinib In Central America And Caribbean NCT01033981 | Pfizer | — |
| Completed | Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer NCT01152801 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma NCT01100242 | New Mexico Cancer Research Alliance | Phase 2 |
| Terminated | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients NCT01073644 | Pfizer | — |
| Unknown | Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma NCT01481870 | Yamagata University | Phase 3 |
| Completed | Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcin NCT01028638 | University Medical Center Groningen | — |
| Unknown | Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer NCT01274273 | University of Aarhus | Phase 2 |
| Completed | Clinical Trial to Assess the Importance of Nephrectomy NCT00930033 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Terminated | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer NCT00942058 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Terminated | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients NCT00913913 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Terminated | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell C NCT00930345 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma NCT00848640 | Egyptian Foundation For Cancer Research | Phase 2 |
| Completed | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma NCT00414765 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | A Phase II Study of AS1411 in Renal Cell Carcinoma NCT00740441 | Antisoma Research | Phase 2 |
| Completed | A Study for Participants With Metastatic Renal Cell Carcinoma NCT00709995 | Eli Lilly and Company | Phase 2 |
| Completed | Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated NCT00684645 | Pfizer | — |
| Unknown | Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma NCT01219751 | Asan Medical Center | Phase 2 |
| Completed | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma NCT00619268 | Centre Leon Berard | Phase 2 |
| Completed | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma NCT00625768 | Antisoma Research | Phase 1 |
| Completed | Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00357760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma NCT00515697 | Eli Lilly and Company | Phase 2 |
| Completed | Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) NCT00570882 | Asan Medical Center | Phase 2 |
| Completed | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients NCT01182142 | Kidney Cancer Research Bureau | Phase 2 |
| Completed | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell C NCT00444314 | CASI Pharmaceuticals, Inc. | Phase 2 |
| Completed | A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who NCT00531544 | King Faisal Specialist Hospital & Research Center | N/A |
| Completed | The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma NCT00554515 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Ki NCT00410124 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma NCT00318110 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients NCT00421512 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer NCT00142415 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Completed | Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma NCT00630409 | University of Pittsburgh | Phase 2 |
| Completed | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma NCT00606866 | University of Chicago | Phase 3 |
| Completed | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell NCT00068393 | Eastern Cooperative Oncology Group | Phase 2 |
| Terminated | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. NCT00151645 | Rennes University Hospital | Phase 2 |
| Completed | Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma NCT01689766 | Endocyte | Phase 2 |
| Terminated | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinom NCT00203866 | University of Chicago | Phase 2 |
| Completed | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Ca NCT01689662 | Endocyte | Phase 2 |
| Completed | Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis NCT00291369 | Centre Leon Berard | Phase 3 |